Kamada Announces Expansion of Biosimilars Portfolio with the Launch of Two Additional Products in Israel

Kamada expects its biosimilar portfolio to include products licensed from six international companies by 2030.

Rhea-AI Summary

Kamada (KMDA) expanded its biosimilar portfolio with the commercial launch of Ustekinumab-Kamada and Enoxaparin-Kamada in Israel, bringing its marketed portfolio to four products. All four were approved and launched as interchangeable with their original reference biologic products.

The company expects at least two additional biosimilars to become commercially available during 2027. It anticipates approximately $4 million in 2026 sales from its existing commercial biosimilar portfolio, growing to approximately $10 million in 2028. By 2030, Kamada expects at least 12 marketed products commercialized in Israel and the Middle East and North Africa, generating approximately $20 million to $25 million in annual revenue.

7 points · 0 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 0 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Moderate point. Forward-looking: it has not happened yet and may not happen.Biosimilar portfolio expected to generate approximately $20 million to $25 million in annual revenue by 2030.
• Moderate pointUstekinumab-Kamada and Enoxaparin-Kamada commercially launched in Israel, expanding the marketed biosimilar portfolio to four products.
• Minor point. Forward-looking: it has not happened yet and may not happen.Existing commercial biosimilar portfolio sales anticipated at approximately $4 million in 2026, growing to approximately $10 million in 2028.
• Minor pointAll four biosimilars approved and launched as interchangeable with their original reference biologic products.
• Minor point. Forward-looking: it has not happened yet and may not happen.At least two additional biosimilars expected to become commercially available during 2027.

2 minor points

• Minor point. Forward-looking: it has not happened yet and may not happen.Kamada expects at least 12 marketed products from six licensors, commercialized in Israel and MENA by 2030.
• Minor point. Forward-looking: it has not happened yet and may not happen.Additional licensed biosimilars expected to be in development or registration by 2030.

Negative

• None.

Key Figures

New biosimilar products launched: 2 products Expected biosimilar sales: Approximately $4 million Expected biosimilar revenue: Approximately $10 million annually +3 more

New biosimilar products launched

2 products

Commercial launch in Israel

Expected biosimilar sales

Approximately $4 million

2026

Expected biosimilar revenue

Approximately $10 million annually

2028

Expected biosimilar revenue

Approximately $20 million-$25 million annually

By 2030

Expected marketed products

At least 12 products

Portfolio expectation by 2030

Expected additional product availability

At least 2 products

During 2027

Key Terms

biosimilar, monoclonal antibody, low-molecular-weight heparin, thromboembolic disorders

4 terms

biosimilar medical

"expansion of its biosimilar portfolio with the commercial launch"

A biosimilar is a medicine created to be highly similar to an existing complex drug made from living cells, matching its safety and effectiveness while allowing for small, natural variations. For investors, biosimilars matter because they introduce lower-cost competition when patents end, which can cut prices, shift market share, and change revenue forecasts for companies selling the original drugs, much like a generic version does for simpler chemical medicines.

monoclonal antibody medical

"a monoclonal antibody indicated for the treatment of chronic immune-mediated"

A monoclonal antibody is a laboratory-made protein designed to recognize and attach to a specific target in the body, such as a disease-causing substance or cell. It functions like a highly precise lock-and-key tool, helping to treat or detect illnesses. For investors, companies developing monoclonal antibodies can represent promising opportunities in the healthcare sector, especially as these treatments often address unmet medical needs.

low-molecular-weight heparin medical

"a low-molecular-weight heparin indicated for the prevention and treatment"

A class of anticoagulant drugs made by chemically or enzymatically breaking unfractionated heparin into smaller fragments; they enhance the activity of antithrombin to inhibit clotting enzymes—particularly factor Xa more than thrombin (factor IIa)—and are used to prevent and treat blood clots. Low-molecular-weight heparins are usually given by subcutaneous injection, have more predictable dose–response and longer half-lives than unfractionated heparin (so routine laboratory monitoring is generally not required), are cleared mainly by the kidneys (requiring dose adjustment or caution in renal impairment), and are only partly reversible with protamine sulfate.

thromboembolic disorders medical

"for the prevention and treatment of thromboembolic disorders"

Thromboembolic disorders are medical conditions in which blood clots form inside blood vessels (thrombosis) and either block blood flow where they form or break off and travel through the circulation to lodge elsewhere (embolism). They include well-known syndromes such as deep vein thrombosis and pulmonary embolism and arise from factors that promote clot formation, impaired blood flow, or damage to vessel walls; clinically they are diagnosed by imaging or laboratory tests and treated with anticoagulant or clot‑removal therapies depending on location and severity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Company Expects Growing Biosimilar Product Portfolio, Commercialized in Israel and the MENA Region, to Generate Approximately $10 Million in Annual Revenue in 2028 and Approximately $20 Million-$25 Million in Annual Revenue by 2030

REHOVOT, Israel and HOBOKEN, N.J., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced the expansion of its biosimilar portfolio with the commercial launch of two additional new products in Israel, adding to its existing portfolio of two products.

The two newly launched biosimilar products are Ustekinumab-Kamada, a biosimilar to Stelara®, a monoclonal antibody indicated for the treatment of chronic immune-mediated inflammatory diseases, including plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis, and Enoxaparin-Kamada, a biosimilar to Clexane®, a low-molecular-weight heparin indicated for the prevention and treatment of thromboembolic disorders, including deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as for use in certain acute coronary syndrome settings.

The launch of the new products is in addition to the Company’s first two biosimilar products, Bevacizumab-Kamada, a biosimilar to Avastin® (Bevacizumab), and Pegfilgrastim-Kamada, a biosimilar to Neulasta®, which were launched in the Israeli market over the last two years. The Company expects the commercial availability of at least two additional biosimilar products during 2027.

All four biosimilar products were approved and launched as interchangeable with the reference original biologic product.

Kamada’s existing commercial portfolio of biosimilars is anticipated to generate approximately $4 million in sales in 2026, growing to approximately $10 million in 2028. By 2030, the Company expects this strategic portfolio to include at least 12 marketed products, licensed from 6 different leading international biosimilar companies, to be commercialized in Israel and the Middle East and North Africa (MENA) region, with the expectation to generate between approximately $20 million to $25 million in annual revenue. Kamada expects that additional biosimilar products, licensed by Kamada, will be in development or registration phase by 2030, contributing to further meaningful expansion of the portfolio.

“Kamada is building a growing and diversified biosimilars portfolio across key therapeutic areas. Our biosimilar regulatory expertise, commercialization infrastructure and market-access capabilities in Israel and the MENA region make us an attractive in-licensing partner, and we are pleased to have launched two additional biosimilars,” said Amir London, Kamada’s Chief Executive Officer. “The growth of our biosimilar product portfolio is one of our key strategic growth pillars. We continue to evaluate additional licensing opportunities that offer attractive commercial potential, and we expect this portfolio to become a meaningful contributor to our overall annual revenue growth in the years ahead.”

About Kamada
Kamada Ltd. (the “Company”) is a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field. FIMI Opportunity Funds, the leading private equity firm in Israel, is the Company’s controlling shareholder, beneficially owning approximately 38% of the outstanding ordinary shares. The Company’s strategy is focused on driving profitable growth through four primary growth pillars: First, organic growth of its commercial portfolio, including continued investment in the commercialization and life cycle management of its proprietary products, consisting of six FDA-approved specialty plasma-derived products: KEDRAB®, GLASSIA®, CYTOGAM®, VARIZIG®, WINRHO SDF® and HEPAGAM B®, as well as KAMRAB®, and two equine-based anti-snake venom products. Second, distribution of third parties' pharmaceutical products in Israel & the MENA region through in-licensing partnerships, including the launch of several biosimilar products in Israel. Third, the Company is ramping up its plasma collection operations to support revenue growth through the sale of normal source plasma to other plasma-derived manufacturers, and to support its increasing demand for hyper-immune plasma. The Company currently owns three FDA approved operating plasma collection centers in the United States, in Beaumont, Houston, and San Antonio, Texas. Fourth, the Company aims to secure new mergers and acquisitions, business development, in-licensing and/or collaboration opportunities, which are anticipated to enhance the Company’s marketed products portfolio and leverage its financial strength and existing commercial infrastructure to drive long-term profitable growth. The Company is leveraging its manufacturing, research and development expertise to advance the development and commercialization of additional product candidates, targeting areas of significant unmet medical need.

Cautionary Note Regarding Forward-Looking Statements
This release includes forward-looking statements within the meaning of Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, including statements regarding: 1) the expected expansion, composition and geographic reach of Kamada’s biosimilar product portfolio; 2) the anticipated timing of the commercial availability and launch of additional biosimilar products; 3) the expected sales and annual revenue contribution of Kamada’s biosimilar product portfolio, including the anticipated generation of approximately $4 million in sales in 2026, approximately $10 million in sales in 2028 and approximately $20 million–$25 million in annual revenue by 2030; 4) the expected number of marketed biosimilar products and licensing partners by 2030; 5) the development or registration status of additional licensed biosimilar products and their potential contribution to further portfolio expansion; 6) Kamada’s ability to leverage its biosimilar regulatory expertise, commercialization infrastructure and market-access capabilities in Israel and the MENA region to remain an attractive in-licensing partner and to identify, evaluate, enter into and successfully commercialize additional in-licensing opportunities that offer attractive commercial potential; and 7) the anticipated contribution of Kamada’s biosimilar product portfolio to its future annual revenue growth, including the expectation that the portfolio will become a meaningful contributor to such growth in the years ahead. Forward-looking statements are based on Kamada’s current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to the evolving nature of the conflicts in the Middle East and the impact of such conflicts in Israel, the Middle East and the rest of the world, the impact of these conflicts on market conditions and the general economic, industry and political conditions in Israel, the U.S. and globally, the effect of tariffs on overall international trade and specifically on Kamada’s ability to continue maintaining expected sales and profit levels in light of such tariffs, the effect on the establishment and timing of business initiatives, Kamada’s ability to find business development and M&A transactions and leverage such opportunities and successfully integrate such opportunities with its existing product portfolio, unexpected results of clinical and development programs, regulatory delays, and other risks detailed in Kamada’s filings with the U.S. Securities and Exchange Commission (the “SEC”) including those discussed in its most recent Annual Report on Form 20-F and in any subsequent reports on Form 6-K, each of which is on file or furnished with the SEC and available at the SEC’s website at www.sec.gov. The forward-looking statements made herein speak only as of the date of this announcement and Kamada undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.

CONTACTS:
Chaime Orlev
Chief Financial Officer
IR@kamada.com

Brian Ritchie
LifeSci Advisors, LLC
212-915-2578
britchie@LifeSciAdvisors.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Which biosimilars did Kamada launch in Israel?

Kamada launched Ustekinumab-Kamada, a biosimilar to Stelara, and Enoxaparin-Kamada, a biosimilar to Clexane. They join Bevacizumab-Kamada and Pegfilgrastim-Kamada, which were launched in Israel over the last two years.

How much biosimilar revenue does Kamada expect by 2030?

Kamada expects its biosimilar portfolio to generate approximately $20 million to $25 million in annual revenue by 2030. Its outlook includes at least 12 marketed products licensed from six international biosimilar companies and commercialized in Israel and the Middle East and North Africa.